Product/Composition:- | Sitagliptin Tablets |
---|---|
Strength:- | 25 mg, 50 mg, 100 mg |
Form:- | Tablets |
Reference Brands:- | Januvia(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sitagliptin is a DPP-4 inhibitor that enhances incretin levels, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. This improves glycemic control without causing hypoglycemia. It’s weight-neutral, well-tolerated, and effective as monotherapy or in combination therapy for Type 2 diabetes, supporting long-term blood sugar regulation.
Sitagliptin, marketed under the brand name Januvia, is a DPP-4 inhibitor approved for managing type 2 diabetes mellitus. In the USA, the FDA approved Sitagliptin in 2006, and it remains under brand protection with limited generic availability. In the EU, it received EMA approval in 2007 and is available in multiple strengths (25 mg, 50 mg, 100 mg). Sitagliptin is used as monotherapy or in combination with other antidiabetic agents. Pharmacovigilance data confirms a favorable safety profile. With patent expirations approaching in some regions, generic versions are beginning to enter select EU markets. Widely sourced via platforms like Pharmatradz.com.